US2779780A
(en)
|
1955-03-01 |
1957-01-29 |
Du Pont |
1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
|
US3935230A
(en)
|
1972-10-24 |
1976-01-27 |
E. R. Squibb & Sons, Inc. |
α, α, α, α', α', α'-Hexafluorodi-m-tolylamine derivatives
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
DE4134467A1
(de)
|
1991-10-18 |
1993-04-22 |
Thomae Gmbh Dr K |
Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
|
US5587458A
(en)
|
1991-10-07 |
1996-12-24 |
Aronex Pharmaceuticals, Inc. |
Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
|
DE69334255D1
(de)
|
1992-02-06 |
2009-02-12 |
Novartis Vaccines & Diagnostic |
Marker für Krebs und biosynthetisches Bindeprotein dafür
|
US6177401B1
(en)
|
1992-11-13 |
2001-01-23 |
Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften |
Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5441952A
(en)
|
1993-04-05 |
1995-08-15 |
Merck & Co., Inc. |
Fibrinogen receptor antagonists
|
EP0647450A1
(de)
|
1993-09-09 |
1995-04-12 |
BEHRINGWERKE Aktiengesellschaft |
Verbesserte Prodrogen für Enzym-vermittelten-Aktivierungen
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
CZ313397A3
(cs)
|
1995-04-04 |
1998-03-18 |
Glaxo Group Limited |
Imidazo/1,2a/pyridinové deriváty, způsob jejich výroby a farmaceutický prostředek s jejich obsahem
|
PT821671E
(pt)
|
1995-04-20 |
2001-04-30 |
Pfizer |
Derivados do acido arilsulfonil hidroxamico como inibidores de mmp e tnf
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
GB9520822D0
(en)
|
1995-10-11 |
1995-12-13 |
Wellcome Found |
Therapeutically active compounds
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
DE69624081T2
(de)
|
1995-12-20 |
2003-06-12 |
Hoffmann La Roche |
Matrix-metalloprotease Inhibitoren
|
DE69637855D1
(de)
|
1995-12-22 |
2009-04-16 |
Novo Nordisk As |
Verbindungen mit wachstumshormon-freisetzenden eigenschaften
|
KR100489174B1
(ko)
|
1996-03-05 |
2005-09-30 |
제네카-파마 소시에떼아노님 |
4-아닐리노퀴나졸린유도체
|
EP0818442A3
(de)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclische Sulphonderivate als Metalloproteinase-Inhibitoren und zur Hemmung der Produktion von Tumornekrosefaktor
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
ID19609A
(id)
|
1996-07-13 |
1998-07-23 |
Glaxo Group Ltd |
Senyawa-senyawa heterosiklik
|
DE69718472T2
(de)
|
1996-07-13 |
2003-11-06 |
Glaxo Group Ltd |
Bicyclische heteroaromatische verbindungen als protein tyrosine kinase inhibitoren
|
TR199900066T2
(xx)
|
1996-07-18 |
1999-04-21 |
Pfizer Inc. |
Matriks metalloproteazlar�n fosfinat bazl� inhibit�rleri
|
TR199900387T2
(xx)
|
1996-08-23 |
1999-04-21 |
Pfizer Inc. |
Arils�lfonilamino hidroksamik asit t�revleri.
|
ATE480521T1
(de)
|
1996-10-01 |
2010-09-15 |
Kyowa Hakko Kirin Co Ltd |
Stickstoff enthaltende heterocyclische verbindungen
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
CA2277100C
(en)
|
1997-01-06 |
2005-11-22 |
Pfizer Inc. |
Cyclic sulfone derivatives
|
EA002594B1
(ru)
|
1997-02-03 |
2002-06-27 |
Пфайзер Продактс Инк. |
Производные арилсульфониламиногидроксамовой кислоты
|
AU5493598A
(en)
|
1997-02-07 |
1998-08-26 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
CN1247531A
(zh)
|
1997-02-11 |
2000-03-15 |
辉瑞大药厂 |
芳基磺酰基异羟肟酸衍生物
|
WO1998050356A1
(en)
|
1997-05-07 |
1998-11-12 |
Sugen, Inc. |
2-indolinone derivatives as modulators of protein kinase activity
|
WO1998054093A1
(en)
|
1997-05-30 |
1998-12-03 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
PT1003720E
(pt)
|
1997-08-08 |
2004-07-30 |
Pfizer Prod Inc |
Derivados de acido ariloxiarilsulfonilamino hidroxamico
|
AU8816298A
(en)
|
1997-08-22 |
1999-03-16 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
WO1999016755A1
(en)
|
1997-09-26 |
1999-04-08 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
IL135636A0
(en)
|
1997-11-11 |
2001-05-20 |
Pfizer Prod Inc |
Thienopyrimidine and thienopyridine derivatives useful as anticancer agents
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
DE69917124T2
(de)
|
1998-04-10 |
2005-05-12 |
Pfizer Products Inc., Groton |
Cyclobutyl-Aryloxysulfonylamin-Hydroxamsäurederivate
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
CA2314156C
(en)
|
1998-05-29 |
2010-05-25 |
Sugen, Inc. |
Pyrrole substituted 2-indolinone protein kinase inhibitors
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
PT1004578E
(pt)
|
1998-11-05 |
2004-06-30 |
Pfizer Prod Inc |
Derivados hidroxamida do acido 5-oxo-pirrolidino-2-carboxilico
|
HUP0104693A3
(en)
|
1998-12-16 |
2003-12-29 |
Warner Lambert Co |
Treatment of arthritis with mek inhibitors
|
UA71945C2
(en)
|
1999-01-27 |
2005-01-17 |
Pfizer Prod Inc |
Substituted bicyclic derivatives being used as anticancer agents
|
EA200100766A1
(ru)
|
1999-02-11 |
2002-02-28 |
Пфайзер Продактс Инк. |
Хинолин-2-он замещенные гетероарильные производные, используемые в качестве противоопухолевых агентов
|
IL129299A0
(en)
|
1999-03-31 |
2000-02-17 |
Mor Research Applic Ltd |
Monoclonal antibodies antigens and diagnosis of malignant diseases
|
CA3016482A1
(en)
|
1999-11-30 |
2001-06-07 |
Mayo Foundation For Medical Education And Research |
B7-h1, a novel immunoregulatory molecule
|
CN1329390C
(zh)
|
2000-02-15 |
2007-08-01 |
苏根公司 |
吡咯取代的2-二氢吲哚酮蛋白激酶抑制剂
|
WO2001060816A1
(en)
|
2000-02-17 |
2001-08-23 |
Amgen Inc. |
Kinase inhibitors
|
CN1219753C
(zh)
|
2000-07-19 |
2005-09-21 |
沃尼尔·朗伯公司 |
4-碘苯氨基苯氧肟酸的氧合酯
|
CN100358890C
(zh)
|
2000-08-18 |
2008-01-02 |
千年药物股份有限公司 |
喹唑啉衍生物类激酶抑制剂
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
MXPA04008722A
(es)
|
2002-03-08 |
2005-07-13 |
Eisai Co Ltd |
Compuestos macrociclicos utiles como farmaceuticos.
|
HUE025767T2
(en)
|
2002-03-13 |
2016-05-30 |
Array Biopharma Inc |
N3-alkylated benzimidazole derivatives as MEK inhibitors
|
AU2003231231A1
(en)
|
2002-05-06 |
2003-11-11 |
Bayer Pharmaceuticals Corporation |
Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
|
IL149820A0
(en)
|
2002-05-23 |
2002-11-10 |
Curetech Ltd |
Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
|
PT2206517T
(pt)
|
2002-07-03 |
2023-11-07 |
Tasuku Honjo |
Composições de imunopotenciação contendo anticorpos anti-pd-l1
|
WO2004024895A2
(en)
|
2002-09-16 |
2004-03-25 |
Plexxikon, Inc. |
Crystal structure of pim-1 kinase
|
AU2003297161B8
(en)
|
2002-12-18 |
2011-03-31 |
Vertex Pharmaceuticals Incorporated |
Triazolopyridazines as protein kinases inhibitors
|
ES2367430T3
(es)
|
2002-12-23 |
2011-11-03 |
Wyeth Llc |
Anticuerpos contra pd-1 y sus usos.
|
JP2006151810A
(ja)
|
2002-12-26 |
2006-06-15 |
Daiichi Asubio Pharma Co Ltd |
ジヒドロチエノキノリン誘導体及びそれを含む細胞接着阻害剤
|
BRPI0407384A
(pt)
|
2003-02-14 |
2006-02-21 |
Pfizer Prod Inc |
piridinas-triazóis como compostos antiinflamatórios
|
WO2004074244A2
(en)
|
2003-02-20 |
2004-09-02 |
Smithkline Beecham Corporation |
Pyrimidine compounds
|
JP2007505858A
(ja)
|
2003-09-18 |
2007-03-15 |
ノバルティス アクチエンゲゼルシャフト |
増殖性障害の処置に有用な2,4−ジ(フェニルアミノ)ピリミジン
|
SI1678166T1
(sl)
|
2003-10-14 |
2009-10-31 |
Univ Arizona State |
Inhibitorji proteinske kinaze
|
PL1778686T3
(pl)
|
2004-08-12 |
2009-04-30 |
Pfizer |
Pochodne triazolopirydynylosulfanylowe jako inhibitory kinazy MAP P38
|
TW200633990A
(en)
|
2004-11-18 |
2006-10-01 |
Takeda Pharmaceuticals Co |
Amide compound
|
US7723340B2
(en)
|
2005-01-13 |
2010-05-25 |
Signal Pharmaceuticals, Llc |
Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith
|
CA2499782A1
(en)
*
|
2005-03-07 |
2006-09-07 |
Queen's University At Kingston |
Sol gel functionalized silicate catalyst and scavenger
|
WO2006116733A2
(en)
|
2005-04-28 |
2006-11-02 |
Supergen, Inc. |
Protein kinase inhibitors
|
ES2427646T5
(es)
|
2005-05-09 |
2017-08-22 |
Ono Pharmaceutical Co., Ltd. |
Anticuerpos monoclonales humanos contra muerte programada 1 (PD1) y métodos para el tratamiento del cáncer mediante el uso de anticuerpos anti-PD-1 solos o combinados con otros agentes inmunoterapéuticos
|
MX2007015942A
(es)
|
2005-07-01 |
2008-03-07 |
Medarex Inc |
Anticuerpos monoclonales humanos para ligandos 1 (pd-l1) de muerte programada.
|
PL1912636T3
(pl)
|
2005-07-21 |
2015-02-27 |
Ardea Biosciences Inc |
N-(aryloamino)sulfonamidowe inhibitory mek
|
US20100216798A1
(en)
|
2005-07-29 |
2010-08-26 |
Astellas Pharma Inc |
Fused heterocycles as lck inhibitors
|
EP1923388A4
(de)
|
2005-08-12 |
2011-03-09 |
Takeda Pharmaceutical |
Gehirn-/nervenzellenschutzmittel und therapeutikum für schlafstörungen
|
US20070049591A1
(en)
|
2005-08-25 |
2007-03-01 |
Kalypsys, Inc. |
Inhibitors of MAPK/Erk Kinase
|
US7750000B2
(en)
|
2005-09-02 |
2010-07-06 |
Bayer Schering Pharma Ag |
Substituted imidazo[1,2b]pyridazines as kinase inhibitors, their preparation and use as medicaments
|
DE102005042742A1
(de)
|
2005-09-02 |
2007-03-08 |
Schering Ag |
Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
|
AR056206A1
(es)
|
2005-10-06 |
2007-09-26 |
Schering Corp |
Pirazolpirimidinas como inhibidores de protein quinasas
|
WO2007087068A2
(en)
|
2006-01-13 |
2007-08-02 |
Pharmacyclics, Inc. |
Inhibitors of tyrosine kinases and uses thereof
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
US20090012079A1
(en)
|
2006-02-09 |
2009-01-08 |
Russell Andrew Lewthwaite |
Triazolopyridine Compounds
|
CN101490001A
(zh)
|
2006-06-09 |
2009-07-22 |
Icos股份有限公司 |
用作dp-2拮抗剂的取代的苯乙酸
|
DE102006029447A1
(de)
|
2006-06-21 |
2007-12-27 |
Bayer Schering Pharma Ag |
Oxo-substituierte Imidazo[1,2b]pyridazine, deren Herstellung und Verwendung als Arzneimittel
|
EP1873157A1
(de)
|
2006-06-21 |
2008-01-02 |
Bayer Schering Pharma Aktiengesellschaft |
Pyrazolopyrimidinen und deren Salze, diese enthaltende pharmazeutische Zusammensetzungen, Methoden zu deren Herstellung und deren Verwendung
|
EP1900739A1
(de)
|
2006-08-30 |
2008-03-19 |
Cellzome Ag |
Diazolodiazin-Derivate als Kinase Inhibitoren
|
WO2008030579A2
(en)
|
2006-09-07 |
2008-03-13 |
Biogen Idec Ma Inc. |
Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
|
CN102887900B
(zh)
|
2006-09-22 |
2015-04-29 |
药品循环公司 |
布鲁顿酪氨酸激酶的抑制剂
|
ATE502943T1
(de)
|
2006-09-29 |
2011-04-15 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
KR20090075714A
(ko)
|
2006-10-30 |
2009-07-08 |
노파르티스 아게 |
소염제로서의 헤테로시클릭 화합물
|
US20080207632A1
(en)
|
2006-10-31 |
2008-08-28 |
Supergen, Inc. |
Protein kinase inhibitors
|
US8987233B2
(en)
|
2006-11-03 |
2015-03-24 |
Pharmacyclics, Inc. |
Bruton's tyrosine kinase activity probe and method of using
|
BRPI0718029A2
(pt)
|
2006-11-06 |
2013-11-26 |
Supergen Inc |
Derivados de imidazo(1,2-b)piridazina e pirazolo(1,5-a)pirimidina e seu uso como inibidores da proteína cinase
|
US20120058997A1
(en)
|
2006-11-06 |
2012-03-08 |
Supergen, Inc. |
Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
|
WO2008082839A2
(en)
|
2006-12-29 |
2008-07-10 |
Abbott Laboratories |
Pim kinase inhibitors as cancer chemotherapeutics
|
US8846704B2
(en)
|
2007-01-31 |
2014-09-30 |
YM Biosciences Austraila Pty Ltd |
Thiopyrimidine-based compounds and uses thereof
|
US8822497B2
(en)
|
2007-03-01 |
2014-09-02 |
Novartis Ag |
PIM kinase inhibitors and methods of their use
|
WO2008106635A1
(en)
|
2007-03-01 |
2008-09-04 |
Supergen, Inc. |
Pyrimidine-2,4-diamine derivatives and their use as jak2 kinase inhibitors
|
US7834024B2
(en)
|
2007-03-26 |
2010-11-16 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the JAK pathway
|
US20120101114A1
(en)
|
2007-03-28 |
2012-04-26 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
EP2954900A1
(de)
|
2007-03-28 |
2015-12-16 |
Pharmacyclics, Inc. |
Hemmer der bruton-tyrosinkinase
|
EP2139869A2
(de)
|
2007-04-13 |
2010-01-06 |
SuperGen, Inc. |
Axl-kinasehemmer
|
US9244059B2
(en)
|
2007-04-30 |
2016-01-26 |
Immutep Parc Club Orsay |
Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
|
EP1987839A1
(de)
|
2007-04-30 |
2008-11-05 |
I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale |
Zytotoxischer monoklonaler Anti-LAG-3-Antikörper und seine Verwendung bei der Behandlung und Vorbeugung von Organtransplantatabstoßung und Autoimmunerkrankungen
|
RS53072B
(en)
|
2007-06-18 |
2014-04-30 |
Merck Sharp & Dohme B.V. |
HUMAN RECEPTOR ANTIBODIES PROGRAMMED DEATH PD-1
|
WO2009017954A1
(en)
|
2007-08-01 |
2009-02-05 |
Phenomix Corporation |
Inhibitors of jak2 kinase
|
US8247397B2
(en)
|
2007-09-12 |
2012-08-21 |
Genentech, Inc. |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
EP2044949A1
(de)
|
2007-10-05 |
2009-04-08 |
Immutep |
Verwendung von rekombinantem LAG-3 oder Derivaten daraus zur Auslösung einer Monozyten-Immunreaktion
|
JP5348725B2
(ja)
|
2007-10-25 |
2013-11-20 |
ジェネンテック, インコーポレイテッド |
チエノピリミジン化合物の製造方法
|
EP2217601A1
(de)
|
2007-11-08 |
2010-08-18 |
Centro Nacional de Investigaciones Oncológicas (CNIO) |
Imidazopyridazine zur vewendung als proteinkinaseinhibitoren
|
WO2009064486A2
(en)
|
2007-11-15 |
2009-05-22 |
Musc Foundation For Research Development |
Inhibitors of pim protein kinases, compositions, and methods for treating cancer
|
NZ586662A
(en)
|
2007-12-19 |
2012-08-31 |
Vertex Pharma |
PYRAZOLO[1,5-a]PYRIMIDINES USEFUL AS JANUS KINASE 2 INHIBITORS
|
EP2234986A2
(de)
|
2007-12-20 |
2010-10-06 |
Cellzome Limited |
Sulfamide als zap-70-hemmer
|
AR070531A1
(es)
|
2008-03-03 |
2010-04-14 |
Novartis Ag |
Inhibidores de cinasa pim y metodos para su uso
|
US8168794B2
(en)
|
2008-03-03 |
2012-05-01 |
Novartis Ag |
Pim kinase inhibitors and methods of their use
|
EP2262837A4
(de)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
Pd-1-bindende proteine
|
MX2010012703A
(es)
|
2008-05-21 |
2010-12-21 |
Ariad Pharma Inc |
Derivados fosforosos como inhibidores de cinasa.
|
US20100035875A1
(en)
|
2008-06-20 |
2010-02-11 |
Bing-Yan Zhu |
Triazolopyridine jak inhibitor compounds and methods
|
WO2009158571A1
(en)
|
2008-06-27 |
2009-12-30 |
Avila Therapeutics And Uses Thereof |
Heteroaryl compounds and uses thereof
|
FR2933409B1
(fr)
|
2008-07-03 |
2010-08-27 |
Centre Nat Rech Scient |
NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
|
EP2307025B1
(de)
|
2008-07-16 |
2017-09-20 |
Pharmacyclics LLC |
Hemmer der bruton-tyrosinkinase zur behandlung fester tumore
|
BRPI0917575A2
(pt)
|
2008-08-05 |
2019-09-24 |
Targegen Inc |
métodos de tratamento de talassemia
|
AR072999A1
(es)
|
2008-08-11 |
2010-10-06 |
Medarex Inc |
Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
|
US8557809B2
(en)
|
2008-08-19 |
2013-10-15 |
Array Biopharma Inc. |
Triazolopyridine compounds as PIM kinase inhibitors
|
TWI496779B
(zh)
|
2008-08-19 |
2015-08-21 |
Array Biopharma Inc |
作為pim激酶抑制劑之三唑吡啶化合物
|
EP2328919A2
(de)
|
2008-08-25 |
2011-06-08 |
Amplimmune, Inc. |
Pd-i-antagonisten und verfahren zur behandlung von infektionserkrankungen
|
CN102203079B
(zh)
|
2008-09-02 |
2014-12-10 |
诺华股份有限公司 |
作为激酶抑制剂的吡啶甲酰胺衍生物
|
EP2342190A1
(de)
|
2008-09-02 |
2011-07-13 |
Novartis AG |
Bicyclische kinaseinhibitoren
|
EA201100427A1
(ru)
|
2008-09-02 |
2011-10-31 |
Новартис Аг |
Гетероциклические ингибиторы киназы
|
AU2009290544B2
(en)
|
2008-09-12 |
2015-07-16 |
Oxford University Innovation Limited |
PD-1 specific antibodies and uses thereof
|
RS53350B
(en)
|
2008-09-22 |
2014-10-31 |
Array Biopharma, Inc. |
SUBSTITUTED COMPOUNDS OF IMIDASO [1,2-B] PYRIDASINE AS INK KINASE INHIBITORS
|
PL2342226T3
(pl)
|
2008-09-26 |
2017-01-31 |
Dana-Farber Cancer Institute, Inc. |
Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
|
HUE034832T2
(hu)
|
2008-12-09 |
2021-12-28 |
Hoffmann La Roche |
Anti-PD-L1 antitestek és alkalmazásuk T-sejt-funkció fokozására
|
TW201035100A
(en)
|
2008-12-19 |
2010-10-01 |
Cephalon Inc |
Pyrrolotriazines as ALK and JAK2 inhibitors
|
CA2758916A1
(en)
|
2009-04-15 |
2010-10-21 |
Pui-Kai Li |
Curcumin analogs as dual jak2/stat3 inhibitors and methods of making and using the same
|
BRPI1011066A2
(pt)
|
2009-05-20 |
2017-03-21 |
Cylene Pharmaceuticals Inc |
"pirazolopirimidinas e heterociclos relacionados como inibidores de quinase
|
WO2010148351A1
(en)
|
2009-06-18 |
2010-12-23 |
Cylene Pharmaceuticals, Inc. |
Rhodanines and related heterocycles as kinase inhibitors
|
TW201107329A
(en)
|
2009-07-30 |
2011-03-01 |
Oncotherapy Science Inc |
Fused imidazole derivative having ttk inhibitory action
|
US7741330B1
(en)
|
2009-10-12 |
2010-06-22 |
Pharmacyclics, Inc. |
Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase
|
EP2332917B1
(de)
|
2009-11-11 |
2012-08-01 |
Sygnis Bioscience GmbH & Co. KG |
Verbindungen zur PIM-Kinasehemmung und zur Behandlung von Malignitäten
|
US20130017199A1
(en)
|
2009-11-24 |
2013-01-17 |
AMPLIMMUNE ,Inc. a corporation |
Simultaneous inhibition of pd-l1/pd-l2
|
ES2646863T3
(es)
|
2009-11-24 |
2017-12-18 |
Medimmune Limited |
Agentes de unión específica contra B7-H1
|
WO2011076519A1
(en)
|
2009-12-22 |
2011-06-30 |
Unilever Nv |
A process for preparing a tea product
|
CN102884062B
(zh)
|
2009-12-23 |
2016-08-03 |
嘉世高制药公司 |
氨基嘧啶激酶抑制剂
|
UY33213A
(es)
|
2010-02-18 |
2011-09-30 |
Almirall Sa |
Derivados de pirazol como inhibidores de jak
|
EP2545078A1
(de)
|
2010-03-11 |
2013-01-16 |
UCB Pharma, S.A. |
Pd-1-antikörper
|
NZ789041A
(en)
|
2010-06-03 |
2023-09-29 |
Pharmacyclics Llc |
The use of inhibitors of bruton’s tyrosine kinase (btk)
|
EP3363499A1
(de)
|
2010-06-11 |
2018-08-22 |
Kyowa Hakko Kirin Co., Ltd. |
Anti-tim-3-antikörper
|
US9163087B2
(en)
|
2010-06-18 |
2015-10-20 |
The Brigham And Women's Hospital, Inc. |
Bi-specific antibodies against TIM-3 and PD-1 for immunotherapy in chronic immune conditions
|
US8907053B2
(en)
|
2010-06-25 |
2014-12-09 |
Aurigene Discovery Technologies Limited |
Immunosuppression modulating compounds
|
CN103080106A
(zh)
|
2010-07-06 |
2013-05-01 |
诺瓦提斯公司 |
用作激酶抑制剂的环醚化合物
|
TWI541243B
(zh)
|
2010-09-10 |
2016-07-11 |
拜耳知識產權公司 |
經取代咪唑并嗒
|
RU2652638C2
(ru)
|
2010-12-17 |
2018-04-28 |
НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. |
Замещенные пиразолхиназолиновые производные в качестве ингибиторов киназы
|
EP2678329B1
(de)
|
2011-02-25 |
2015-11-18 |
Array Biopharma Inc. |
Triazolopyridin verbindungen als pim kinase hemmer
|
WO2012120415A1
(en)
|
2011-03-04 |
2012-09-13 |
Novartis Ag |
Tetrasubstituted cyclohexyl compounds as kinase inhibitors
|
EP2688886A1
(de)
|
2011-03-22 |
2014-01-29 |
Amgen Inc. |
Azolverbindungen als pim-inhibitoren
|
MX338353B
(es)
|
2011-04-20 |
2016-04-13 |
Medimmune Llc |
Anticuerpos y otras moleculas que se unen a b7 - h1 y pd - 1.
|
JP6200884B2
(ja)
|
2011-06-14 |
2017-09-20 |
ノバルティス アーゲー |
骨髄増殖性腫瘍などの癌の治療におけるパノビノスタットおよびルキソリチニブの組合せ
|
WO2012177606A1
(en)
|
2011-06-20 |
2012-12-27 |
Incyte Corporation |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
WO2013006490A2
(en)
|
2011-07-01 |
2013-01-10 |
Cellerant Therapeutics, Inc. |
Antibodies that specifically bind to tim3
|
EA201490265A1
(ru)
|
2011-07-13 |
2014-12-30 |
Фармасайкликс, Инк. |
Ингибиторы тирозинкиназы брутона
|
PT3409278T
(pt)
|
2011-07-21 |
2020-12-18 |
Sumitomo Dainippon Pharma Oncology Inc |
Inibidores de proteína cinase heterocíclicos
|
US8686119B2
(en)
|
2011-07-24 |
2014-04-01 |
Curetech Ltd. |
Variants of humanized immunomodulatory monoclonal antibodies
|
CN102924445B
(zh)
|
2011-08-11 |
2015-07-08 |
上海吉铠医药科技有限公司 |
Pim激酶抑制剂及其制备方法与在制药中的应用
|
US20140303191A1
(en)
|
2011-10-19 |
2014-10-09 |
Pharmacyclics, Inc. |
Use of inhibitors of bruton's tyrosine kinase (btk)
|
JP6138813B2
(ja)
|
2011-11-28 |
2017-05-31 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングMerck Patent Gesellschaft mit beschraenkter Haftung |
抗pd−l1抗体及びその使用
|
US8377946B1
(en)
|
2011-12-30 |
2013-02-19 |
Pharmacyclics, Inc. |
Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
|
US8501724B1
(en)
|
2012-01-31 |
2013-08-06 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
RU2014140739A
(ru)
|
2012-03-09 |
2016-04-27 |
Лексикон Фармасьютикалз, Инк. |
Соединения на основе имидазо[1, 2-b]пиридазина, композиции таких соединений и способы их применения
|
WO2013173518A1
(en)
|
2012-05-16 |
2013-11-21 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
WO2013175388A1
(en)
|
2012-05-21 |
2013-11-28 |
Novartis Ag |
Novel ring-substituted n-pyridinyl amides as kinase inhibitors
|
KR20220084444A
(ko)
|
2012-05-31 |
2022-06-21 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Pd-l1에 결합하는 항원 결합 단백질
|
KR20200017549A
(ko)
|
2012-06-04 |
2020-02-18 |
파마싸이클릭스 엘엘씨 |
브루톤 타이로신 키나아제 저해제의 결정 형태
|
UY34887A
(es)
|
2012-07-02 |
2013-12-31 |
Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware |
Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
|
EP2877598A1
(de)
|
2012-07-24 |
2015-06-03 |
Pharmacyclics, Inc. |
Mutationen im zusammenhang mit der resistenz gegenüber hemmern der bruton-tyrosinkinase (btk)
|
US8703981B2
(en)
|
2012-08-03 |
2014-04-22 |
Xerox Corporation |
Lignosulfonate compounds for solid ink applications
|
EP2890715B1
(de)
|
2012-08-03 |
2020-12-16 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1- und pd-l2-doppelbindende antikörper in form eines einzelnen wirkstoffes und verfahren zur verwendung
|
HUE031955T2
(en)
|
2012-08-06 |
2017-08-28 |
Acea Biosciences Inc |
New pyrrole pyrimidine compounds as inhibitors of protein kinases
|
KR101446742B1
(ko)
|
2012-08-10 |
2014-10-01 |
한국화학연구원 |
N2,n4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
|
CN102880459A
(zh)
|
2012-08-14 |
2013-01-16 |
张涛 |
基于VisualLisp编程语言下的编译实现方法及系统
|
US9315514B2
(en)
|
2012-08-27 |
2016-04-19 |
Rhodes Technologies |
1,3-dioxanomorphides and 1,3-dioxanocodides
|
WO2014033631A1
(en)
|
2012-08-31 |
2014-03-06 |
Novartis Ag |
N-(3-pyridyl) biarylamides as kinase inhibitors
|
EP2900668A4
(de)
|
2012-09-26 |
2016-04-20 |
Mannkind Corp |
Hemmer mehrerer kinasewege
|
CN107892719B
(zh)
|
2012-10-04 |
2022-01-14 |
达纳-法伯癌症研究所公司 |
人单克隆抗-pd-l1抗体和使用方法
|
MX2015006168A
(es)
|
2012-11-15 |
2015-08-10 |
Pharmacyclics Inc |
Compuestos de pirrolopirimidina como inhibidores de quinasas.
|
AR093984A1
(es)
|
2012-12-21 |
2015-07-01 |
Merck Sharp & Dohme |
Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
|
JP6554037B2
(ja)
|
2013-01-15 |
2019-07-31 |
インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation |
Pimキナーゼ阻害剤として有用なチアゾールカルボキサミドおよびピリジンカルボキサミド化合物
|
JP2016509012A
(ja)
|
2013-02-08 |
2016-03-24 |
セルジーン アビロミクス リサーチ, インコーポレイテッド |
Erk阻害剤およびそれらの使用
|
US10322125B2
(en)
|
2013-02-22 |
2019-06-18 |
Emory University |
TGF-beta enhancing compositions for cartilage repair and methods related thereto
|
WO2014130693A1
(en)
|
2013-02-25 |
2014-08-28 |
Pharmacyclics, Inc. |
Inhibitors of bruton's tyrosine kinase
|
AU2014244518A1
(en)
|
2013-03-14 |
2015-09-17 |
Pharmacyclics Llc |
Combinations of Bruton's tyrosine kinase inhibitors and CYP3A4 inhibitors
|
CA2905993C
(en)
|
2013-03-14 |
2022-12-06 |
Tolero Pharmaceuticals, Inc. |
Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
|
EP2970464B1
(de)
|
2013-03-15 |
2020-05-06 |
GlaxoSmithKline Intellectual Property Development Limited |
Anti-lag-3 bindende proteine
|
AU2014251028A1
(en)
|
2013-04-08 |
2015-11-05 |
Janssen Pharmaceutica Nv |
Ibrutinib combination therapy
|
CN105339389B
(zh)
|
2013-05-02 |
2021-04-27 |
安奈普泰斯生物有限公司 |
针对程序性死亡-1(pd-1)的抗体
|
CA3175360C
(en)
|
2013-05-31 |
2024-05-28 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind pd-1
|
KR102094011B1
(ko)
|
2013-06-13 |
2020-03-26 |
삼성전자주식회사 |
전자 장치에서 노이즈를 제거하기 위한 장치 및 방법
|
WO2014209804A1
(en)
|
2013-06-24 |
2014-12-31 |
Biomed Valley Discoveries, Inc. |
Bispecific antibodies
|
WO2015002894A1
(en)
|
2013-07-02 |
2015-01-08 |
Pharmacyclics, Inc. |
Purinone compounds as kinase inhibitors
|
CN105611928A
(zh)
|
2013-08-08 |
2016-05-25 |
诺华股份有限公司 |
Pim激酶抑制剂组合
|
AU2014308703A1
(en)
|
2013-08-23 |
2016-03-24 |
Incyte Corporation |
Furo- and thieno-pyridine carboxamide compounds useful as Pim kinase inhibitors
|
JP6623353B2
(ja)
|
2013-09-13 |
2019-12-25 |
ベイジーン スウィッツァーランド ゲーエムベーハー |
抗pd−1抗体並びにその治療及び診断のための使用
|
US9624224B2
(en)
|
2013-09-30 |
2017-04-18 |
Pharmacyclics Llc |
Inhibitors of Bruton's tyrosine kinase
|
EP3060581A4
(de)
|
2013-10-25 |
2017-06-07 |
Dana-Farber Cancer Institute, Inc. |
Anti-pd-l1 monoklonale antikörper und fragmente davon
|
WO2015081158A1
(en)
|
2013-11-26 |
2015-06-04 |
Bristol-Myers Squibb Company |
Method of treating hiv by disrupting pd-1/pd-l1 signaling
|
AU2014354821A1
(en)
|
2013-11-27 |
2016-05-26 |
Novartis Ag |
Combination therapy comprising an inhibitor of JAK, CDK and PIM
|
CN105026428B
(zh)
|
2013-12-12 |
2018-01-16 |
上海恒瑞医药有限公司 |
PD‑l抗体、其抗原结合片段及其医药用途
|
EP4079321A1
(de)
|
2014-01-15 |
2022-10-26 |
Kadmon Corporation, LLC |
Immunmodulatorische mittel
|
TWI681969B
(zh)
|
2014-01-23 |
2020-01-11 |
美商再生元醫藥公司 |
針對pd-1的人類抗體
|
TWI680138B
(zh)
|
2014-01-23 |
2019-12-21 |
美商再生元醫藥公司 |
抗pd-l1之人類抗體
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
BR112016017174A2
(pt)
|
2014-01-28 |
2017-10-03 |
Bristol Myers Squibb Co |
Anticorpos anti-lag-3 para tratar malignidades hematológicas
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
CN106103484B
(zh)
|
2014-03-14 |
2021-08-20 |
诺华股份有限公司 |
针对lag-3的抗体分子及其用途
|
ES2829914T3
(es)
|
2014-04-08 |
2021-06-02 |
Incyte Corp |
Tratamiento de enfermedades malignas de células B mediante una combinación de inhibidor de JAK y PI3K
|
TW201545749A
(zh)
|
2014-04-25 |
2015-12-16 |
Univ Nat Cheng Kung |
樟芝酸a、一種jak2/3酪胺酸激酶抑制劑及有潛力的肝炎治療劑
|
DK3149042T3
(da)
|
2014-05-29 |
2019-11-04 |
Spring Bioscience Corp |
PD-L1-antistoffer og anvendelser deraf
|
WO2015195163A1
(en)
|
2014-06-20 |
2015-12-23 |
R-Pharm Overseas, Inc. |
Pd-l1 antagonist fully human antibody
|
TWI693232B
(zh)
|
2014-06-26 |
2020-05-11 |
美商宏觀基因股份有限公司 |
與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
|
TWI687438B
(zh)
|
2014-07-03 |
2020-03-11 |
英屬開曼群島商百濟神州生物科技有限公司 |
抗pd-l1抗體及其作為治療及診斷之用途
|
JO3663B1
(ar)
|
2014-08-19 |
2020-08-27 |
Merck Sharp & Dohme |
الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
|
UY36351A
(es)
|
2014-10-14 |
2016-06-01 |
Novartis Ag |
Moléculas de anticuerpo que se unen a pd-l1 y usos de las mismas
|
EP3632935A1
(de)
|
2014-11-06 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Anti-tim3-antikörper und verfahren zur verwendung
|
TWI595006B
(zh)
|
2014-12-09 |
2017-08-11 |
禮納特神經系統科學公司 |
抗pd-1抗體類和使用彼等之方法
|
US20160200815A1
(en)
|
2015-01-05 |
2016-07-14 |
Jounce Therapeutics, Inc. |
Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
|
TW201639888A
(zh)
|
2015-03-06 |
2016-11-16 |
索倫多醫療公司 |
結合tim3之抗體治療劑
|
MA41867A
(fr)
|
2015-04-01 |
2018-02-06 |
Anaptysbio Inc |
Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
|
WO2016161248A1
(en)
|
2015-04-02 |
2016-10-06 |
Tolero Pharmaceuticals, Inc. |
Targeting pim kinases in combination with btk inhibition
|
WO2017106647A1
(en)
*
|
2015-12-16 |
2017-06-22 |
Genentech, Inc. |
Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
|
CN105919955A
(zh)
|
2016-06-13 |
2016-09-07 |
佛山市腾瑞医药科技有限公司 |
一种鲁索利替尼制剂及其应用
|
JP2021521170A
(ja)
|
2018-04-13 |
2021-08-26 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
骨髄増殖性新生物およびがんに関連する線維症の処置のためのpimキナーゼ阻害剤
|
JP2022520361A
(ja)
|
2019-02-12 |
2022-03-30 |
スミトモ ダイニッポン ファーマ オンコロジー, インコーポレイテッド |
複素環式タンパク質キナーゼ阻害剤を含む製剤
|
JP2022552880A
(ja)
|
2019-10-21 |
2022-12-20 |
セルジーン コーポレーション |
置換4-アミノイソインドリン-1,3-ジオン化合物および組合せ使用のための第2の活性剤
|